Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Video
Can Biosimilars Reduce Specialty Spending?
Author(s):
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.
Related Videos
Related Content
